Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:5
  • preuzimanja u poslednjih 30 dana:1
članak: 6 od 31  
Back povratak na rezultate
Hospital Pharmacology - International Multidisciplinary Journal
2016, vol. 3, br. 2, str. 409-415
jezik rada: engleski
vrsta rada: kratki članak
objavljeno: 09/09/2016
doi: 10.5937/hpimj1602409V
Creative Commons License 4.0
Uloga metformina u tretmanu dijabetesa tipa 2 i gojaznosti
Education Center, General Hospital Valjevo, Valjevo

e-adresa: vmira62@gmail.com

Sažetak

Tema: Međusobna udruženost i proučavanje povezanosti između gojaznosti, visceralne gojaznosti, smanjene osetljivosti na insulin (sa posledičnom hiperinsulinemijom), dijabetesa tip 2, dislipoproteinemija i antropometrijskih karakteristika pacijenata sa metaboličkim sindromom, predmet su mnogih epidemioloških studija. Međutim, primećuje se da postoji neslaganje i kontradiktornost u definisanju antropometrijskih i metaboličkih faktora rizika za nastanak kardiovaskularnih, cerebrovaskularnih i drugih vaskularnih oboljenja, posebno u populaciji gojaznih pacijenata sa dijabetesom tip 2. Pozicioniranost teme u medicinskoj javnosti: Teorijski, metformin postiže dobru glikoregulaciju upravo kod visceralno gojaznih bolesnika. Ovo se objašnjava većom glikometaboličkom aktivnošću visceralnog masnog tkiva u odnosu na supkutanu mast. Buduće aktivnosti: Efikasnija redukcija visceralnog masnog tkiva kod pacijenata sa postignutom boljom glikoregulacijom pod uticajem metformina, rezultat je njegovih kompleksnih mehanizama dejstva. Metformin igra važnu ulogu u smanjenju kardiovaskularnog rizika koji potiče od povišene visceralne gojaznosti, paralelno sa postizanjem dobre glikoregulacije kod gojaznih bolesnika sa dijabetesom tip 2.

Ključne reči

Reference

Aldhahi, W., Hamdy, O. (2003) Adipokines, inflammation, and the endothelium in diabetes. Current diabetes reports, 3(4): 293-8
Bailey, C.J., Turner, R.C. (1996) Metformin. N Engl J Med, 334(9): 574-9
Bailey, C.J. (1993) Metformin: An update. Gen Pharmacol Nov, 24, str. 1299-1309
Bays, H.E., González-Campoy, J.M., Henry, R.R., Bergman, D.A., Kitabchi, A.E., Schorr, A.B., Rodbard, H.W., Group The Adiposopathy Working (2008) Is adiposopathy (sick fat) an endocrine disease?. International Journal of Clinical Practice, 62(10): 1474-1483
Bays, H.E., González-Campoy, J., Bray, G.A., Kitabchi, A.E., Bergman, D.A., Schorr, A.B., Rodbard, H.W., Henry, R.R. (2008) Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert review of cardiovascular therapy, 6(3): 343-68
Brambilla, P., Bedogni, G., Moreno, L.A., Goran, M.I., Gutin, B., Fox, K.R., Peters, D.M., Barbeau, P., i dr. (2006) Crossvalidation of anthropometry against magnetic resonance imaging for the assessment of visceral and subcutaneous adipose tissue in children. International Journal of Obesity, 30(1): 23
Catalano, K.J., Stefanovski, D., Bergman, R.N. (2010) Critical Role of the Mesenteric Depot Versus Other Intra-abdominal Adipose Depots in the Development of Insulin Resistance in Young Rats. Diabetes, 59(6): 1416-1423
Cigolini, M., Bosello, O., Zancanaro, C., Orlandi, P.G., Fezzi, O., Smith, U. (1984) Influence of metformin on metabolic effect of insulin in human adipose tissue in vitro. Diabet Metab, 10, 311-315
Dubois, S.G., Heilbronn, L.K., Smith, S.R., Albu, J.B., Kelley, D.E., Ravussin, E. (2006) Decreased Expression of Adipogenic Genes in Obese Subjects with Type 2 Diabetes*. Obesity, 14(9): 1543-1552
Frayn, K.N. (2000) Visceral fat and insulin resistance - causative or correlative?. British Journal of Nutrition, 83( Suppl1):S71-S77
Fried, S.K., Bunkin, D.A., Greenberg, A.S. (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab, 83(3): 847-50
Fujimoto, W.Y., Jablonski, K.A., Bray, G.A., Kriska, A., Barrett-Connor, E., Haffner, S., Hanson, R., Hill, J.O., Hubbard, V., Stamm, E., Pi-Sunyer, F.X., Group for the Diabetes Prevention Program Research (2007) Body Size and Shape Changes and the Risk of Diabetes in the Diabetes Prevention Program. Diabetes, 56(6): 1680-1685
Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., i dr. (2005) Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science, 307, str. 426-30
Galuska, D., Nolte, L.A., Zierath, J.R., Wallberg-Henriksson, H. (1994) Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia, 37(8): 826-32
Gastaldelli, A. (2008) Abdominal fat: does it predict the development of type 2 diabetes?. American journal of clinical nutrition, 87(5): 1118-9
Heilbronn, L., Smith, S.R., Ravussin, E. (2004) Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. International Journal of Obesity, 28: S12-S21
Kim, S., Hur, K., Kim, H., Shim, W., Ahn, C., Park, S., Cho, Y., Lim, S., Lee, H., Cha, B. (2007) The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment. European journal of endocrinology, 157(2): 167-74
Kozka, I.J., Holman, G.D. (1993) Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes, 42(8): 1159-65
Kraja, A.T., Province, M.A., Arnett, D., Wagenknecht, L., Tang, W., Hopkins, P.N., Djoussé, L., Borecki, I.B. (2007) Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster?. Nutrition & Metabolism, 4(1): 28
Lakka, T.A., Lakka, H.M., Salonen, R., Kaplan, G.A., Salonen, J.T. (2001) Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis, 154(2): 497-504
Lapčević, M., Vuković, M., Dimitrijević, I., Kalezić, N., Ristić, J. (2007) Uticaj medikamentnog i nemedikamentnog lečenja na smanjenje faktora rizika za kardiovaskularne i cerebrovaskularne događaje u interventnoj studiji. Srpski arhiv za celokupno lekarstvo, vol. 135, br. 9-10, str. 554-561
Lim, C.T., Kola, B., Korbonits, M. (2010) AMPK as a mediator of hormonal signalling. Journal of molecular endocrinology, 44(2): 87-97
Matthaei, S., Hamann, A., Klein, H.H., Benecke, H., Kreymann, G., Flier, J.S., Greten, H. (1991) Association of Metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes. Diabetes, 40(7): 850-7
Miyatake, N., Takenami, S., Fujii, M. (2004) Evaluation of visceral adipose accumulation in Japanese women and establishment of a predictive formula. Acta diabetologica, 41(3): 113-7
Montague, C.T., Prins, J.B., Sanders, L., Zhang, J., Sewter, C.P., Digby, J., Byrne, C.D., O`Rahilly, S. (1998) Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes, 47(9): 1384-91
Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., Zinman, B. (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care, 32(1): 193
Oikari, S., Ahtialansaari, T., Heinonen, M.V., Mauriala, T., Auriola, S., Kiehne, K., Fölsch, U.R., Jänne, J., Alhonen, L., Herzig, K. (2008) Downregulation of PPARs and SREBP by acyl-CoA-binding protein overexpression in transgenic rats. Pflügers Archiv, 456(2): 369-77
Prada, P.O., Ropelle, E.R., Mourao, R.H., de Souza, C.T., Pauli, J.R., Cintra, D.E., Schenka, A., Rocco, S.A., Rittner, R., Franchini, K.G., Vassallo, J., Velloso, L.A., Carvalheira, J.B., Saad, M.J.A. (2009) EGFR Tyrosine Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet-Fed Mice. Diabetes, 58(12): 2910-2919
Rossetti, L., DeFronzo, R.A., Gherzi, R., Stein, P., Andraghetti, G., Falzetti, G., Shulman, G.I., Klein-Robbenhaar, E., Cordera, R. (1990) Effect of metformin treatment on insulin action in diabetic rats: In vivo and in vitro correlations. Metabolism, 39(4): 425-35
Schneider, J., Erren, T., Zofel, P., Kaffarnik, H. (1990) Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus. Atherosclerosis, 82(1-2): 97-103
Stanforth, P.R., Jackson, A.S., Green, J.S., Gagnon, J., Rankinen, T., Desprès, J., Bouchard, C., Leon, A.S., Rao, D.C., Skinner, J.S., Wilmore, J.H. (2004) Generalized abdominal visceral fat prediction models for black and white adults aged 17-65 y: the HERITAGE Family Study. International Journal of Obesity, 28(7): 925-932
Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S., Lazar, M.A. (2001) The hormone resistin links obesity to diabetes. Nature, 409(6818): 307-12
St-Pierre, J., Lemieux, I., Perron, P., Brisson, D., Santuré, M., Vohl, M., Després, J., Gaudet, D. (2007) Relation of the 'hypertriglyceridemic waist' phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. American journal of cardiology, 99(3): 369-73
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., Gerich, J.E. (1995) Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med, 333(9): 550-4
UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352(9131): 854-65
UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352(9131): 837-53
Vuković, M., Gvozdenović, B.S. (2008) Klasteri bolesnika sa dijabetes melitusom tip 2 lečenih metforminom. Opšta medicina, vol. 14, br. 1-2, str. 32-36
Vuković, M., Lapčević, M., Kalezić, N., Gvozdenović, B.S. (2007) The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2. Srpski arhiv za celokupno lekarstvo, vol. 135, br. 7-8, str. 447-452
Widen, E., Lehto, M., Kanninen, T., i dr. (2004) Association of polymorphism in the B3-adrenergic receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med, 333, 348-351
Wollen, N., Bailey, C.J. (1988) Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. Biochemical pharmacology, 37(22): 4353-8
Yokota, T., Oritani, K., Takahashi, I., Ishikawa, J., Matsuyama, A., Ouchi, N., Kihara, S., Funahashi, T., Tenner, A.J., Tomiyama, Y., Matsuzawa, Y. (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 96(5): 1723-32
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., i dr. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108(8), str. 1167-74